版本:
中国

BRIEF-Medtronic says data from surtavi trial showed co's self-expanding TAVR platform met primary endpoint at 2 years

March 17 Medtronic Plc

* Landmark surtavi clinical trial shows transcatheter aortic valve replacement (tavr) with the self-expanding platform performs as well as surgery in intermediate risk severe aortic stenosis patients

* Medtronic plc- data from surtavi trial showed co's self-expanding tavr platform met primary endpoint at 2 years

* Medtronic plc - results of surtavi trial have been submitted to fda to support an intermediate risk label expansion Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐